-
Ganetespib (STA-9090) Workflow for Hsp90 Studies
2026-09-03
Ganetespib (STA-9090) combines high-potency Hsp90 inhibition with a practical workflow for dose-response, client-protein degradation, and tumor-model studies. This guide translates product specifications and a selective protein-secretion study into actionable assay design, controls, and troubleshooting decisions.
-
α2-adrenergic receptor agonist Workflow
2026-09-03
Build reproducible α2-AR signaling assays with a DMSO-soluble UK14,304 research tool designed for receptor and immune-microenvironment studies. This workflow connects concentration control, local hydrogel delivery, and immune-aware controls to post-surgery osteosarcoma recurrence research.
-
Bestatin as a Chemical Probe of Jasmonate Signaling
2026-09-02
The reference study established bestatin as a chemical genetic probe that activates jasmonate responses through COI1-dependent signaling, even when endogenous jasmonic acid biosynthesis is not strictly required. Its combination of transcript profiling, developmental phenotyping, and bestatin-resistant mutant screening provides a practical framework for identifying previously unrecognized regulators of plant hormone signaling.
-
Nelfinavir Mesylate: From HIV to Ferroptosis
2026-09-02
Nelfinavir Mesylate offers translational researchers a clinically informed HIV-1 protease inhibition tool and a mechanistic entry point into DDI2-NFE2L1 regulation, proteasome adaptation, and ferroptosis sensitization.
-
How P-gp Inhibition Raises Luteolin Bioavailability
2026-09-01
The reference study developed a luteolin-loaded self-microemulsifying drug delivery system that combines improved dispersion with D-α-tocopheryl polyethylene glycol 1000 succinate-mediated inhibition of P-glycoprotein efflux. The formulation enhanced Caco-2 cellular uptake, showed favorable preliminary biosafety, and increased luteolin systemic exposure by 29-fold in pharmacokinetic testing, providing a useful model for oral delivery of poorly absorbed bioactives.
-
GSK 2837808A LDHA Inhibition Workflows
2026-09-01
GSK 2837808A is a selective LDHA tool for separating lactate production from broader glycolytic activity in cancer-cell experiments. This workflow connects validated hepatocellular carcinoma applications with carefully bounded, hypothesis-generating studies of lactate-linked immune signaling in colorectal cancer.
-
Nicotinamide Adenine Dinucleotide in Stress Assays
2026-08-31
Use NAD+ to add a quantitative metabolic layer to studies of caspase-dependent autophagy and DNA damage responses. This workflow combines controlled NAD+ handling with NAD+/NADH measurements, autophagy readouts, PARP1 processing, and H2AX phosphorylation to distinguish metabolic adaptation from lethal stress.
-
In Vitro Drug Response Metrics in Cancer Research
2026-08-31
Hannah R. Schwartz’s dissertation separates relative viability from fractional viability to clarify how cancer drugs produce growth arrest and cell killing. Its central implication is practical: drug-response studies should measure proliferation and death as related but distinct outcomes, ideally across time rather than at one endpoint.
-
Merimepodib (VX-497) Research Workflows
2026-08-30
Merimepodib (VX-497) enables controlled IMPDH inhibition for antiviral, lymphocyte, and proliferation assays. This workflow guide translates recent PEDV metabolism findings into practical experimental design, controls, and troubleshooting strategies.
-
ARCA EGFP mRNA: Storage-to-Assay Guide
2026-08-29
ARCA EGFP mRNA (5-moUTP) is a polyadenylated mRNA reporter for controlled fluorescence readouts in mammalian cells. This guide connects molecular design with storage, handling, assay architecture, and the practical limits of translating LNP-RNA stability findings to reporter workflows.
-
Cyclic di-GMP: Biofilm and STING Workflows
2026-08-28
Cyclic di-GMP connects bacterial biofilm persistence studies with mammalian STING-based immune modulation. This practical guide covers formulation, assay design, protocol starting points, controls, and troubleshooting for infection biology and cancer immunotherapy research.
-
Merimepodib (VX-497) IMPDH Research Workflow
2026-08-28
Merimepodib (VX-497) provides a reversible way to interrogate IMPDH-dependent guanine nucleotide biosynthesis in antiviral, lymphocyte, and cell-proliferation models. This applied guide connects formulation, dose selection, orthogonal validation, and troubleshooting to recent evidence that PEDV depends on host IMPDH activity.
-
Dual-Action Inhibitors and p38α Dephosphorylation
2026-08-27
The reference study shows that kinase inhibitors can do more than block p38α catalytic activity: selected compounds also expose the activation-loop phospho-threonine and accelerate its removal by WIP1. By combining biochemical dephosphorylation assays with X-ray crystallography, the work establishes kinase conformation as a potential lever for improving inhibitor specificity, durability, and pathway control.
-
MK-1775: Wee1 Kinase Inhibitor Workflow
2026-08-27
Use MK-1775 to interrogate Wee1-dependent checkpoint control, then separate growth arrest from true cell killing with orthogonal readouts. This workflow is especially useful for testing DNA-damage combinations in p53-deficient models without overinterpreting a single viability endpoint.
-
Multiple Myeloma Cell Lines: Mutations and Drug Response
2026-08-26
Vikova and colleagues used whole-exome sequencing across a genetically diverse panel of human multiple myeloma cell lines to define recurrent coding mutations, altered pathways, and links to drug response. The study provides a practical framework for selecting cell-line models and developing hypotheses about disease progression and treatment resistance.